- Calcium retention capacity is a measure of mitochondrial function
- Capacity and dose-dependence of MPTP inhibitors is measured in high throughput
- POLARstar® Omega enables multiple injections and kinetic assessment of ﬂuorescent calcium sens
Table of contents
Mitochondrial dysfunction is central to the pathogenesis of acute pancreatitis as well as other diseases including ischemia-reperfusion injury of the heart, brain and kidney, muscular dystrophies and neuro-degeneration1-3. Mitochondrial dysfunction is the result of a sudden increase in permeability of the inner mitochondrial membrane (IMM), via persistent opening of a multi-protein channel known as the mitochondrial permeability transition pore (MPTP)1. This allows uncontrolled proton ﬂow across the IMM and unregulated ﬂux of water, ions and solutes up to 1.5 kDa into and out of the mitochondrial matrix. This results in loss of inner mitochondrial-membrane potential, which is essential for ATP production, disruption of calcium homeostasis, swelling of mitochondria and of the outer mitochondrial membrane (OMM). Eventually cells start dying through necrosis in an uncontrolled manner4. Therefore, MPTP could be an attractive target for maintenance of mitochondrial function and cell death prevention in a host of disease states.
Materials & Methods
- Freshly Isolated liver mitochondria
- Calcium Green-5N (Molecular Probes)
- Calcium chloride (Sigma)
- Inhibitors of interest
- Black 96-well microplates (Greiner)
- POLARstar Omega (BMG LABTECH)
Calcium was added every 4 minutes to mouse liver mitochondria in the presence of the ﬂuorescent Ca2+ indicator, Calcium Green 5N. Calcium uptake was followed by measuring extra-mitochondrial calcium green ﬂuorescence until MPTP opening was achieved. Each inhibitor was added to the mitochondria immediately prior to the start Ca2+ of the experiment.
|Optic settings||Fluorescence intensity, plate mode kinetic|
|Filter||Excitation 485 |
|General settings||Number of flashes 10|
|Settling time 0.1 s|
|Kinetic settings||Number of cycles 160|
|Cycle time 30 s|
|Injection settings||Smart dispensing used|
|Volume of pump 4 µl|
|Pump speed 300 µl/s|
|Injection cycle 4|
Results & Discussion
Mostly, sustained mitochondrial matrix Ca2+ overload triggers prolonged high-conductance MPTP opening. Therefore, CRC assay using isolated mitochondria is an excellent tool for phenotypic screening of the MPTP inhibitors. As shown in Figure 2, different inhibitors resist opening of the MPTP to differing extents. The promising candidates can be tested in a concentration dependent manner. As demonstrated in Figure 3, one lead inhibitor showed MPTP inhibition in a concentration dependent manner in the CRC assay.
The MPTP opening and its inhibition can be evaluated by determining the calcium retention capacity (CRC) of mitochondria to Calcium GreenTM-5N, a low-afﬁnity membrane impermeable dye that exhibits an increase in ﬂuorescence emission intensity upon binding to calcium (Fig 1).
A ﬁxed volume of calcium chloride is added to the sample (mitochondrial suspension) at deﬁned intervals, each eliciting a spike in signal that dissipates due to the uptake of calcium into the mitochondrial matrix. Opening of the MPTP collapses the mitochondrial membrane potential, which results in release of the accumulated calcium from the matrix, causing a sudden and sustained increase in ﬂuorescence signal (Fig 2).
CRC assay is a high throughput assay for a screening of the MPTP inhibitors with POLARstar Omega microplate reader. The assay can also be adopted for the live permeabilized cells. Owing to multiple injections and short ﬂuorescent spikes, a robust microplate reader with injectors that detects ﬂuorescence intensity fast and sensitive is required for reading the assay. The POLARstar Omega has proven to meet these requirements. Furthermore, the intuitive operation of the microplate reader by its control software assists in running such complex assays.
1. Bernardi P, Lisa FD (2015) The mitochondrial permeability transition pore: Molecular nature and role as a target in cardioprotection. J. Mol. Cell. Cardiol. 78, 100-106.
2. Rao VK, Carlson EA, Yan SS (2014) Mitochondrial permeability transition pore is a potential drug target for neurodegeneration. Biochim. Biophys. Acta, 1842, 1267-72.
3. Mukherjee R et al. (2016) Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. Gut 65, 1333-46.
4. Nakagawa T et al. (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434, 652-8.